Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
carmustine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| filgrastim | BIOLOGICAL | - |
| rituximab | BIOLOGICAL | - |
| carmustine | DRUG | - |
| cyclophosphamide | DRUG | - |
| cytarabine | DRUG | - |
| etoposide | DRUG | - |
| melphalan | DRUG | - |
| bone marrow ablation with stem cell support | PROCEDURE | - |
| peripheral blood stem cell transplantation | PROCEDURE | - |
DISEASE CHARACTERISTICS: * Relapsed or resistant follicular non-Hodgkin's lymphoma (NHL) * No evidence of transformation to high grade or diffuse large B-cell NHL * CD20 positive with no evidence of transformation * Achievement of complete remission (CR) or very good partial remission (VGPR) fol...
Top 20 of 66 competitors
Carmustine is an alkylating chemotherapy drug being studied for use in lymphoma, specifically in combination chemotherapy with peripheral stem cell transplantation for patients with relapsed non-Hodgkin's lymphoma. It is currently in Phase 3 clinical development as an investigational therapy.
Carmustine is a small molecule that works as an alkylating agent, targeting DNA to prevent cancer cell division. It is being evaluated in lymphoma, where it is used as part of a combination chemotherapy regimen in the context of peripheral stem cell transplantation.
Carmustine is being developed by Solid Biosciences Inc., a biopharmaceutical company traded on NASDAQ under the ticker SLDB. The company is conducting clinical research on the drug for the treatment of lymphoma.
Carmustine is in Phase 3 clinical development for lymphoma. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, with results not yet reported as part of the available data.
Carmustine is associated with one completed Phase 3 clinical trial, NCT00005589, which enrolled 460 patients with relapsed non-Hodgkin's lymphoma. The trial studied combination chemotherapy plus peripheral stem cell transplantation with or without rituximab across multiple countries.
Carmustine is also known by the brand name BiCNU. It is an alkylating chemotherapy agent used in oncology. In the context of the available data, it is being studied for lymphoma, and the name BiCNU is commonly used interchangeably with carmustine in clinical settings.